AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

AstraZeneca agreed to acquire a 12% stake in Summit Therapeutics at a valuation above what Summit's shares command in the open market, signaling a divergence between the pharma company's view and public-market pricing of ivonescimab. Two clinical milestones due in 2026 are positioned as the key catalysts that will determine whether AstraZeneca's investment thesis or Wall Street's skepticism proves correct.